Opportunity Information: Apply for RFA DA 10 011
Apply for RFA DA 10 011
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 3, 2009 and posted on Sep 3, 2009.
- Applicants must submit their applications by Dec 23, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Native American tribal governments (Federally recognized) State governments Native American tribal organizations (other than Federally recognized tribal governments) County governments Special district governments Independent school districts Small businesses For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Private institutions of higher education City or township governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21)" (Funding Opportunity Number RFA-DA-10-011) is a discretionary NIH research grant issued by the National Institute on Drug Abuse (NIDA). Its central goal is to push forward understanding of how epigenomic regulation and non-coding RNAs influence HIV infection and HIV disease processes, specifically in the real-world context where substance use and addiction can shape biology, behavior, treatment access, and disease outcomes. The announcement is positioned as a catalyst for fresh, high-impact ideas, encouraging investigators to test novel hypotheses, open up new directions, or apply new tools to existing questions at the intersection of HIV/AIDS, drug abuse, and epigenomics.
This is an exploratory/developmental award using the NIH R21 mechanism, which is typically geared toward early-stage, proof-of-concept, and higher-risk approaches that can generate compelling preliminary data. The FOA explicitly encourages innovative research and highlights the value of newly formed collaborations, especially teams that combine expertise across HIV/AIDS research, substance use research, and epigenomics (including areas like chromatin structure, DNA methylation, histone modifications, and regulatory non-coding RNAs such as microRNAs and long non-coding RNAs). In practice, that emphasis signals that NIDA is looking not only for strong science, but also for cross-disciplinary projects that might not easily fit within a single traditional research lane.
The R21 opportunity runs in parallel with a companion announcement of identical scientific scope that uses the R01 mechanism (RFA-DA-10-010). Together, the R21 and R01 announcements share a combined set-aside budget of about $2.5 million, with an anticipated 2 to 4 R01 awards and 4 to 6 R21 awards. For this R21 FOA, the award ceiling is listed as $200,000, reinforcing the expectation that proposed studies should be tightly focused, feasible within the smaller budget typical of R21s, and designed to produce decisive preliminary findings or methodological advances rather than large, multi-aim clinical programs.
In terms of eligibility, the announcement is broad and inclusive, covering many types of applicants: higher education institutions (public and private), state and local governments, federally recognized tribal governments and other tribal organizations, nonprofit organizations (including those with and without 501(c)(3) status), small businesses and other for-profit entities, independent school districts, special district governments, public housing authorities/Indian housing authorities, and additional categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, tribally controlled colleges and universities, faith-based or community-based organizations, U.S. territories or possessions, and even non-U.S. (foreign) organizations and regional organizations. The FOA also states there is no cost sharing or matching requirement, which reduces barriers for institutions that may not have flexible institutional funds to commit.
Key administrative details reflect that this was a time-limited solicitation: it was posted on September 3, 2009, with an original and current closing date of December 23, 2009, and an archive date of January 23, 2010. The program is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs), aligning it with NIDA's mission to understand and address substance use and its health impacts, including how drug exposure can interact with infectious diseases like HIV.
Overall, the opportunity can be summarized as a targeted NIH/NIDA call for creative, cross-disciplinary R21 projects that examine epigenomic mechanisms and non-coding RNA biology in HIV/AIDS, with a particular focus on how substance abuse may alter these processes and contribute to infection dynamics, disease progression, or related pathogenesis. The program is designed to seed new collaborations and early-stage ideas that could later mature into larger, more definitive research efforts, potentially including follow-on R01-level studies. For further official details, the announcement links to the NIH Grants Guide page at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-011.html, and NIH provides webmaster contacts for access or linking issues.
FAQs: Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21) (RFA-DA-10-011)
What is the name of this grant opportunity?
The opportunity is titled "Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-DA-10-011.
Which agency and institute are offering this grant?
This is an NIH discretionary research grant issued by the National Institute on Drug Abuse (NIDA).
What is the main purpose or goal of this FOA?
The central goal is to advance understanding of how epigenomic regulation and non-coding RNAs influence HIV infection and HIV disease processes, specifically in real-world settings where substance use and addiction can affect biology, behavior, treatment access, and disease outcomes.
What type of NIH award mechanism is this?
This FOA uses the NIH R21 mechanism, an exploratory/developmental award typically intended for early-stage, proof-of-concept, and higher-risk approaches.
What kinds of projects is the R21 mechanism intended to support in this FOA?
The FOA positions the R21 as a catalyst for fresh, high-impact ideas, encouraging investigators to test novel hypotheses, open new directions, or apply new tools to existing questions at the intersection of HIV/AIDS, drug abuse, and epigenomics. The expectation is that proposed studies are tightly focused and designed to produce decisive preliminary findings or methodological advances.
What scientific areas does this FOA emphasize?
The FOA emphasizes epigenomic regulation and non-coding RNA biology in HIV/AIDS, including areas such as chromatin structure, DNA methylation, histone modifications, and regulatory non-coding RNAs (for example, microRNAs and long non-coding RNAs).
How does substance use or addiction fit into the research focus?
The FOA specifically highlights the importance of studying HIV/AIDS epigenomic and non-coding RNA processes in contexts where substance use and addiction may shape biology, behavior, treatment access, and disease outcomes.
Does the FOA encourage cross-disciplinary teams or collaborations?
Yes. The FOA explicitly encourages innovative research and underscores the value of newly formed collaborations, particularly teams combining expertise across HIV/AIDS research, substance use research, and epigenomics.
Is there a companion funding opportunity with the same scientific scope?
Yes. This R21 FOA runs in parallel with a companion announcement of identical scientific scope using the R01 mechanism: RFA-DA-10-010.
How much funding is available across the combined R21 and R01 announcements?
The R21 and R01 announcements share a combined set-aside budget of about $2.5 million.
How many awards are anticipated?
The FOA anticipates approximately 2 to 4 R01 awards and 4 to 6 R21 awards.
What is the budget ceiling for an award under this R21 FOA?
The award ceiling listed for this R21 FOA is $200,000.
What does the $200,000 award ceiling imply about project scope?
It reinforces that projects should be tightly focused, feasible within a smaller R21 budget, and aimed at generating compelling preliminary data or methodological advances rather than large, multi-aim clinical programs.
Who is eligible to apply?
Eligibility is broad and includes (among others): public and private higher education institutions; state and local governments; federally recognized tribal governments and other tribal organizations; nonprofit organizations (with and without 501(c)(3) status); small businesses and other for-profit entities; independent school districts; special district governments; public housing authorities/Indian housing authorities; and additional categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, tribally controlled colleges and universities, faith-based or community-based organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations and regional organizations.
Are non-U.S. (foreign) organizations eligible?
Yes. The FOA includes non-U.S. (foreign) organizations and regional organizations among the eligible applicant categories.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
When was this FOA posted?
The FOA was posted on September 3, 2009.
What were the closing dates for this opportunity?
The original and current closing date listed is December 23, 2009.
When was the opportunity archived?
The archive date is January 23, 2010.
What CFDA program is associated with this FOA?
The program is listed under CFDA 93.279, Drug Abuse and Addiction Research Programs.
Where can applicants find the official FOA text?
The FOA points to the NIH Grants Guide page: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-10-011.html
What kind of support is mentioned for access or linking issues?
The FOA notes that NIH provides webmaster contacts for access or linking issues related to the official announcement page.
How can this R21 award fit into a longer-term research plan?
The FOA describes the program as designed to seed new collaborations and early-stage ideas that could mature into larger, more definitive research efforts, potentially including follow-on R01-level studies.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: BLM UT Moab FO Canyon Country Fire Zone Riparian Restoration
Previous opportunity: Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 011
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 011) also looked into and applied for these:
| Funding Opportunity |
|---|
| Targeted Library Synthesis and Screening at Novel Targets for Potential Drug Addiction Treatments and Research Tools (R21/R33) Apply for RFA DA 10 005 Funding Number: RFA DA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Apply for RFA GM 10 009 Funding Number: RFA GM 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Developing Research Capacity in Africa for Studies on HIV Associated Malignancies (D43) Apply for RFA CA 09 016 Funding Number: RFA CA 09 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Medications Development for Cannabis Related Disorders (R01) Apply for RFA DA 10 016 Funding Number: RFA DA 10 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) Apply for PAR 10 003 Funding Number: PAR 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 10 002 Funding Number: PAR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 10 001 Funding Number: PAR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (U54) Apply for RFA CA 09 032 Funding Number: RFA CA 09 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Pathway to Independence Award in Cancer Nanotechnology Research (K99/R00) Apply for RFA CA 09 015 Funding Number: RFA CA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Nanotechnology Training Centers (CNTCs)(R25) Apply for RFA CA 09 014 Funding Number: RFA CA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 10 012 Funding Number: PA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 10 011 Funding Number: PA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 10 013 Funding Number: PA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 10 002 Funding Number: RFA CA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) Apply for RFA CA 10 003 Funding Number: RFA CA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 10 005 Funding Number: RFA CA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Cancer Research (R33) Apply for RFA CA 10 004 Funding Number: RFA CA 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 10 001 Funding Number: RFA CA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) Apply for PAR 10 018 Funding Number: PAR 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences (R36) Apply for PAR 10 020 Funding Number: PAR 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 011", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.